請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/53598
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 楊銘欽(Ming-Chin Yang) | |
dc.contributor.author | Pin-Kuei Fu | en |
dc.contributor.author | 傅彬貴 | zh_TW |
dc.date.accessioned | 2021-06-16T02:26:10Z | - |
dc.date.available | 2018-09-14 | |
dc.date.copyright | 2015-09-14 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-08-05 | |
dc.identifier.citation | 中文參考文獻
台灣胸腔暨重症加護醫學會. (2014). 慢性阻塞性肺病2014診治指引. Chronic Obstructive Pulmonary Disease. 台北市. 侯勝茂. (2006). 推展全人照護計畫,健全醫師訓練制度. 台灣醫界, 49(1). 國家衛生研究院. (2015). 全民健康保險研究資料庫, from http://nhird.nhri.org.tw/date_cohort.htm 廖浩欽, 胡百敏, 吳清平, 陳淑芳, & 廖訓禎. (2011). 以健保資料庫資料探究40歲以上慢性阻塞性肺部疾病和支氣管性氣喘病人之診斷與處置. [Using the National Health Insurance Database to Analyze Diagnoses and Treatment Procedures in Chronic Obstructive Lung Disease and Bronchial Asthma in Patients Over 40 Years Old]. 台灣急診專科醫師期刊, 3(4), 105-111. 劉競明. (2010). 健保調漲 醫療品質仍低落, from http://www.appledaily.com.tw/appledaily/article/headline/20100320/32375576/ 衛生福利部. (2014). 102年國人死因統計結果, from http://www.mohw.gov.tw/cht/Ministry/DM2_P.aspx?f_list_no=7&fod_list_no=4558&doc_no=45347 References Aaron, S. D. (2014). Management and prevention of exacerbations of COPD. BMJ, 349, g5237. Aaron, S. D., Vandemheen, K. L., Clinch, J. J., Ahuja, J., Brison, R. J., Dickinson, G., & Hebert, P. C. (2002). Measurement of short-term changes in dyspnea and disease-specific quality of life following an acute COPD exacerbation. Chest, 121(3), 688-696. Aaron, S. D., Vandemheen, K. L., Hebert, P., Dales, R., Stiell, I. G., Ahuja, J.,Wells, G.(2003). Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med, 348(26), 2618-2625. Abrams, T. E., Vaughan-Sarrazin, M., & Van der Weg, M. W. (2011). Acute exacerbations of chronic obstructive pulmonary disease and the effect of existing psychiatric comorbidity on subsequent mortality. Psychosomatics, 52(5), 441-449. Almagro, P., Calbo, E., Ochoa de Echaguen, A., Barreiro, B., Quintana, S., Heredia, J. L., & Garau, J. (2002). Mortality after hospitalization for COPD. Chest, 121(5), 1441-1448. Anthonisen, N. R., Manfreda, J., Warren, C. P., Hershfield, E. S., Harding, G. K., & Nelson, N. A. (1987). Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med, 106(2), 196-204. Anto, J. M., Vermeire, P., Vestbo, J., & Sunyer, J. (2001). Epidemiology of chronic obstructive pulmonary disease. Eur Respir J, 17(5), 982-994. Barnes, P. J. (2008). Future treatments for chronic obstructive pulmonary disease and its comorbidities. Proc Am Thorac Soc, 5(8), 857-864. Barnes, P. J., & Celli, B. R. (2009). Systemic manifestations and comorbidities of COPD. Eur Respir J, 33(5), 1165-1185. Berry, C. E., & Wise, R. A. (2010). Mortality in COPD: causes, risk factors, and prevention. COPD, 7(5), 375-382. Blakemore, A., Dickens, C., Guthrie, E., Bower, P., Kontopantelis, E., Afzal, C., & Coventry, P. A. (2014). Depression and anxiety predict health-related quality of life in chronic obstructive pulmonary disease: systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis, 9, 501-512. Boixeda, R., Bacca, S., Elias, L., Capdevila, J. A., Vila, X., Mauri, M., & Almirall, J. (2014). Pneumonia as comorbidity in chronic obstructive pulmonary disease (COPD). Differences between acute exacerbation of COPD and pneumonia in patients with COPD. Arch Bronconeumol, 50(12), 514-520. Breyer, M. K., Spruit, M. A., Hanson, C. K., Franssen, F. M., Vanfleteren, L. E., Groenen, M. T., Rutten, E. P. (2014). Prevalence of metabolic syndrome in COPD patients and its consequences. PLoS One, 9(6), e98013. Buist, A. S., McBurnie, M. A., Vollmer, W. M., Gillespie, S., Burney, P., Mannino, D. M., Nizankowska-Mogilnicka, E. (2007). International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet, 370(9589), 741-750. Burney, P. G., Patel, J., Newson, R., Minelli, C., & Naghavi, M. (2015). Global and regional trends in COPD mortality, 1990-2010. Eur Respir J. Calverley, P., Pauwels, R., Vestbo, J., Jones, P., Pride, N., Gulsvik, A., Maden, C. (2003). Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet, 361(9356), 449-456. Calverley, P. M., Anderson, J. A., Celli, B., Ferguson, G. T., Jenkins, C., Jones, P. W., Vestbo, J. (2007). Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med, 356(8), 775-789. Casanova, C., Cote, C., de Torres, J. P., Aguirre-Jaime, A., Marin, J. M., Pinto-Plata, V., & Celli, B. R. (2005). Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 171(6), 591-597. CDC. (2005). Chronic Obstructive Pulmonary Disease, 3-1-2009., from http://www.cdc.gov/nchs/fastats/copd.htm Celli, B. R., & MacNee, W. (2004). Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J, 23(6), 932-946. Chan, J. Y., Stern, D. A., Guerra, S., Wright, A. L., Morgan, W. J., & Martinez, F. D. (2015). Pneumonia in childhood and impaired lung function in adults: a longitudinal study. Pediatrics, 135(4), 607-616. Chan, T. C., Chiang, P. H., Su, M. D., Wang, H. W., & Liu, M. S. (2014). Geographic disparity in chronic obstructive pulmonary disease (COPD) mortality rates among the Taiwan population. PLoS One, 9(5), e98170. Chen, S. J., Liao, W. C., Huang, K. H., Lin, C. L., Tsai, W. C., Kung, P. T., Kao, C. H. (2015). Chronic obstructive pulmonary disease is a strong independent risk factor for osteoporosis and pathologic fractures: a population-based cohort study. QJM, 108(8), 633-640. Cheng SL, C. M., Perng DW, Yu CJ. (2014). Epidemiology Survey Of COPD In The Adult Population In Taiwan B42. THE WORLD IS NOT ENOUGH: COPD IS A GLOBAL DISEASE (pp. A2938-A2938): American Thoracic Society. Chorostowska-Wynimko, J. (2015). Targeted screening programmes in COPD: how to identify individuals with alpha1-antitrypsin deficiency. Eur Respir Rev, 24(135), 40-45. Corsonello, A., Antonelli Incalzi, R., Pistelli, R., Pedone, C., Bustacchini, S., & Lattanzio, F. (2011). Comorbidities of chronic obstructive pulmonary disease. Curr Opin Pulm Med, 17 Suppl 1, S21-28. Covino, N. A., Dirks, J. F., Kinsman, R. A., & Seidel, J. V. (1982). Patterns of depression in chronic illness. Psychother Psychosom, 37(3), 144-153. de-Torres, J. P., Wilson, D. O., Sanchez-Salcedo, P., Weissfeld, J. L., Berto, J., Campo, A., Zulueta, J. J. (2015). Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. Am J Respir Crit Care Med, 191(3), 285-291. de Torres, J. P., Pinto-Plata, V., Casanova, C., Mullerova, H., Cordoba-Lanus, E., Muros de Fuentes, M., Celli, B. R. (2008). C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest, 133(6), 1336-1343. de Voogd, J. N., Wempe, J. B., Koeter, G. H., Postema, K., van Sonderen, E., Ranchor, A. V., Sanderman, R. (2009). Depressive symptoms as predictors of mortality in patients with COPD. Chest, 135(3), 619-625. Divo, M., Cote, C., de Torres, J. P., Casanova, C., Marin, J. M., Pinto-Plata, V., Celli, B. (2012). Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 186(2), 155-161. Eriksson, S. (1965). Studies in alpha 1-antitrypsin deficiency. Acta Med Scand Suppl, 432, 1-85. Fabbri, L. M., Luppi, F., Beghe, B., & Rabe, K. F. (2008). Complex chronic comorbidities of COPD. Eur Respir J, 31(1), 204-212. Fan, V. S., Ramsey, S. D., Giardino, N. D., Make, B. J., Emery, C. F., Diaz, P. T., Martinez, F. J. (2007). Sex, depression, and risk of hospitalization and mortality in chronic obstructive pulmonary disease. Arch Intern Med, 167(21), 2345-2353. Fletcher, C., & Peto, R. (1977). The natural history of chronic airflow obstruction. Br Med J, 1(6077), 1645-1648. Ford, E. S. (2014). Trends in mortality from chronic obstructive pulmonary disease among adults in the United States. Chest. doi: 10.1378/chest.14-2311 [Epub ahead of print] Foster, T. S., Miller, J. D., Marton, J. P., Caloyeras, J. P., Russell, M. W., & Menzin, J. (2006). Assessment of the economic burden of COPD in the U.S.: a review and synthesis of the literature. COPD, 3(4), 211-218. Frith, P. A., Thompson, P. J., Ratnavadivel, R., Chang, C. L., Bremner, P., Day, P., Kurstjens, N. (2015). Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study-a randomised controlled trial. Thorax. 70(6), 519-527. Ghoorah, K., De Soyza, A., & Kunadian, V. (2013). Increased cardiovascular risk in patients with chronic obstructive pulmonary disease and the potential mechanisms linking the two conditions: a review. Cardiol Rev, 21(4), 196-202. Gift, A. G., & McCrone, S. H. (1993). Depression in patients with COPD. Heart Lung, 22(4), 289-297. GOLD. (2011). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Update 2011 from www.goldcopd.org. GOLD. (2015). Global Strategy for Diagnosis, Management, and Prevention of COPD, from http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html Groenewegen, K. H., Schols, A. M., & Wouters, E. F. (2003). Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest, 124(2), 459-467. Gross, N. J., Petty, T. L., Friedman, M., Skorodin, M. S., Silvers, G. W., & Donohue, J. F. (1989). Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. A three-center study. Am Rev Respir Dis, 139(5), 1188-1191. Halbert, R. J., Natoli, J. L., Gano, A., Badamgarav, E., Buist, A. S., & Mannino, D. M. (2006). Global burden of COPD: systematic review and meta-analysis. Eur Respir J, 28(3), 523-532. Hasegawa, K., Tsugawa, Y., Tsai, C. L., Brown, D. F., & Camargo, C. A., Jr. (2014). Frequent utilization of the emergency department for acute exacerbation of chronic obstructive pulmonary disease. Respir Res, 15, 40. Higgins, B. G., Powell, R. M., Cooper, S., & Tattersfield, A. E. (1991). Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis. Eur Respir J, 4(4), 415-420. Hill, K., Geist, R., Goldstein, R. S., & Lacasse, Y. (2008). Anxiety and depression in end-stage COPD. Eur Respir J, 31(3), 667-677. Hogg, J. C., Chu, F., Utokaparch, S., Woods, R., Elliott, W. M., Buzatu, L.,Pare, P. D. (2004). The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med, 350(26), 2645-2653. Hu, G., Zhou, Y., Tian, J., Yao, W., Li, J., Li, B., & Ran, P. (2010). Risk of COPD from exposure to biomass smoke: a metaanalysis. Chest, 138(1), 20-31. Hung, C. Y., Wang, K. Y., Wu, T. J., Hsieh, Y. C., Huang, J. L., Loh el, W., & Lin, C. H. (2014). Resistant hypertension, patient characteristics, and risk of stroke. PLoS One, 9(8), e104362. Hurst, J. R., Elborn, J. S., & De Soyza, A. (2015). COPD-bronchiectasis overlap syndrome. Eur Respir J, 45(2), 310-313. Hurst, J. R., Vestbo, J., Anzueto, A., Locantore, N., Mullerova, H., Tal-Singer, R., Wedzicha, J. A. (2010). Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med, 363(12), 1128-1138. Ito, K., Kawayama, T., Shoji, Y., Fukushima, N., Matsunaga, K., Edakuni, N., Hoshino, T. (2012). Depression, but not sleep disorder, is an independent factor affecting exacerbations and hospitalization in patients with chronic obstructive pulmonary disease. Respirology, 17(6), 940-949. Jarvis, S., Ind, P. W., & Shiner, R. J. (2007). Inhaled therapy in elderly COPD patients; time for re-evaluation? Age Ageing, 36(2), 213-218. Johnson, P., Balakrishnan, K., Ramaswamy, P., Ghosh, S., Sadhasivam, M., Abirami, O., Subhashini, A. S. (2011). Prevalence of chronic obstructive pulmonary disease in rural women of Tamilnadu: implications for refining disease burden assessments attributable to household biomass combustion. Glob Health Action, 4, 7226. Jones, P. W., Willits, L. R., Burge, P. S., & Calverley, P. M. (2003). Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J, 21(1), 68-73. Ko, F. W., Hui, D. S., & Lai, C. K. (2008). Worldwide burden of COPD in high- and low-income countries. Part III. Asia-Pacific studies. Int J Tuberc Lung Dis, 12(7), 713-717. Kunik, M. E., Roundy, K., Veazey, C., Souchek, J., Richardson, P., Wray, N. P., & Stanley, M. A. (2005). Surprisingly high prevalence of anxiety and depression in chronic breathing disorders. Chest, 127(4), 1205-1211. Kuo, L. C., Yang, P. C., & Kuo, S. H. (2005). Trends in the mortality of chronic obstructive pulmonary disease in Taiwan, 1981-2002. J Formos Med Assoc, 104(2), 89-93. Kurmi, O. P., Semple, S., Simkhada, P., Smith, W. C., & Ayres, J. G. (2010). COPD and chronic bronchitis risk of indoor air pollution from solid fuel: a systematic review and meta-analysis. Thorax, 65(3), 221-228. Laurin, C., Labrecque, M., Dupuis, G., Bacon, S. L., Cartier, A., & Lavoie, K. L. (2009). Chronic obstructive pulmonary disease patients with psychiatric disorders are at greater risk of exacerbations. Psychosom Med, 71(6), 667-674. Lee, C. T., Mao, I. C., Lin, C. H., Lin, S. H., & Hsieh, M. C. (2013). Chronic obstructive pulmonary disease: a risk factor for type 2 diabetes: a nationwide population-based study. Eur J Clin Invest, 43(11), 1113-1119. Lee, H., Kim, J., & Tagmazyan, K. (2013). Treatment of stable chronic obstructive pulmonary disease: the GOLD guidelines. Am Fam Physician, 88(10), 655-663, 663B-F. Lee, M. S., Lin, R. Y., & Lai, M. S. (2014). Increased risk of diabetes mellitus in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study. J Am Acad Dermatol, 70(4), 691-698. Leuppi, J. D., Schuetz, P., Bingisser, R., Bodmer, M., Briel, M., Drescher, T., Rutishauser, J. (2013). Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA, 309(21), 2223-2231. Li, C. H., Chen, W. C., Liao, W. C., Tu, C. Y., Lin, C. L., Sung, F. C., Hsu, W. H. (2015). The association between chronic obstructive pulmonary disease and Parkinson's disease: a nationwide population-based retrospective cohort study. QJM, 108(1), 39-45. Liao, W. C., Lin, C. L., Chang, S. N., Tu, C. Y., & Kao, C. H. (2015). The association between chronic obstructive pulmonary disease and dementia: a population-based retrospective cohort study. Eur J Neurol, 22(2), 334-340. Lin, C. H., Lin, J. W., Liu, Y. C., Chang, C. H., & Wu, R. M. (2014). Risk of Parkinson's disease following severe constipation: a nationwide population-based cohort study. Parkinsonism Relat Disord, 20(12), 1371-1375. Lindberg, A., Bjerg, A., Ronmark, E., Larsson, L. G., & Lundback, B. (2006). Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med, 100(2), 264-272. Lou, P., Chen, P., Zhang, P., Yu, J., Wang, Y., Chen, N., Zhao, J. (2014). Effects of smoking, depression, and anxiety on mortality in COPD patients: a prospective study. Respir Care, 59(1), 54-61. Lou, P., Zhu, Y., Chen, P., Zhang, P., Yu, J., Zhang, N., Zhao, J. (2012). Prevalence and correlations with depression, anxiety, and other features in outpatients with chronic obstructive pulmonary disease in China: a cross-sectional case control study. BMC Pulm Med, 12, 53. Lundback, B., Gulsvik, A., Albers, M., Bakke, P., Ronmark, E., van den Boom, G., Omenaas, E. (2003). Epidemiological aspects and early detection of chronic obstructive airway diseases in the elderly. Eur Respir J Suppl, 40, 3s-9s. Maclay, J. D., & MacNee, W. (2013). Cardiovascular disease in COPD: mechanisms. Chest, 143(3), 798-807. Mahler, D. A., Wire, P., Horstman, D., Chang, C. N., Yates, J., Fischer, T., & Shah, T. (2002). Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 166(8), 1084-1091. Man, W. D., Mustfa, N., Nikoletou, D., Kaul, S., Hart, N., Rafferty, G. F., Moxham, J. (2004). Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax, 59(6), 471-476. Mannino, D. M., Buist, A. S., Petty, T. L., Enright, P. L., & Redd, S. C. (2003). Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax, 58(5), 388-393. Martinez, F. J., Foster, G., Curtis, J. L., Criner, G., Weinmann, G., Fishman, A.,Wise, R. (2006). Predictors of mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care Med, 173(12), 1326-1334. McGarvey, L. P., Magder, S., Burkhart, D., Kesten, S., Liu, D., Manuel, R. C., & Niewoehner, D. E. (2012). Cause-specific mortality adjudication in the UPLIFT(R) COPD trial: findings and recommendations. Respir Med, 106(4), 515-521. Menezes, A. M., Perez-Padilla, R., Hallal, P. C., Jardim, J. R., Muino, A., Lopez, M. V., Talamo, C. (2008). Worldwide burden of COPD in high- and low-income countries. Part II. Burden of chronic obstructive lung disease in Latin America: the PLATINO study. Int J Tuberc Lung Dis, 12(7), 709-712. Menzin, J., Boulanger, L., Marton, J., Guadagno, L., Dastani, H., Dirani, R., Shah, H. (2008). The economic burden of chronic obstructive pulmonary disease (COPD) in a U.S. Medicare population. Respir Med, 102(9), 1248-1256. Miller, A. H. (2010). Depression and immunity: a role for T cells?. Brain Behav Immun, 24(1), 1-8. Miravitlles, M., Murio, C., Guerrero, T., & Gisbert, R. (2003). Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest, 123(3), 784-791. Molken, M. P., Van Doorslaer, E. K., & Rutten, F. F. (1992). Economic appraisal of asthma and COPD care: a literature review 1980-1991. Soc Sci Med, 35(2), 161-175. Murray, C. J., & Lopez, A. D. (1997). Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet, 349(9061), 1269-1276. Mykletun, A., Bjerkeset, O., Overland, S., Prince, M., Dewey, M., & Stewart, R. (2009). Levels of anxiety and depression as predictors of mortality: the HUNT study. Br J Psychiatry, 195(2), 118-125. Ng, T. P., Niti, M., Tan, W. C., Cao, Z., Ong, K. C., & Eng, P. (2007). Depressive symptoms and chronic obstructive pulmonary disease: effect on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med, 167(1), 60-67. Niewoehner, D. E. (2010). Clinical practice. Outpatient management of severe COPD. N Engl J Med, 362(15), 1407-1416. Niewoehner, D. E., Erbland, M. L., Deupree, R. H., Collins, D., Gross, N. J., Light, R. W., Morgan, N. A. (1999). Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med, 340(25), 1941-1947. Nishimura, K., Izumi, T., Tsukino, M., & Oga, T. (2002). Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest, 121(5), 1434-1440. Nizet, T. A., van den Elshout, F. J., Heijdra, Y. F., van de Ven, M. J., Mulder, P. G., & Folgering, H. T. (2005). Survival of chronic hypercapnic COPD patients is predicted by smoking habits, comorbidity, and hypoxemia. Chest, 127(6), 1904-1910. Norwood, R. (2006). Prevalence and impact of depression in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med, 12(2), 113-117. Nussbaumer-Ochsner, Y., & Rabe, K. F. (2011). Systemic manifestations of COPD. Chest, 139(1), 165-173. O'Donnell, D. E., Fluge, T., Gerken, F., Hamilton, A., Webb, K., Aguilaniu, B., Magnussen, H. (2004). Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J, 23(6), 832-840. Panagioti, M., Scott, C., Blakemore, A., & Coventry, P. A. (2014). Overview of the prevalence, impact, and management of depression and anxiety in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis, 9, 1289-1306. Piquet, J., Chavaillon, J. M., David, P., Martin, F., Blanchon, F., & Roche, N. (2013). High-risk patients following hospitalisation for an acute exacerbation of COPD.. Eur Respir J, 42(4), 946-955. Pooler, A., & Beech, R. (2014). Examining the relationship between anxiety and depression and exacerbations of COPD which result in hospital admission: a systematic review. Int J Chron Obstruct Pulmon Dis, 9, 315-330. Raherison, C., & Girodet, P. O. (2009). Epidemiology of COPD. Eur Respir Rev, 18(114), 213-221. Regional_COPD_Working_Group. (2003). COPD prevalence in 12 Asia-Pacific countries and regions: projections based on the COPD prevalence estimation model. Respirology, 8(2), 192-198. Ryu, Y. J., Chun, E. M., Lee, J. H., & Chang, J. H. (2010). Prevalence of depression and anxiety in outpatients with chronic airway lung disease. Korean J Intern Med, 25(1), 51-57. Sarkar, M., Bhardwaj, R., Madabhavi, I., & Khatana, J. (2015). Osteoporosis in chronic obstructive pulmonary disease. Clin Med Insights Circ Respir Pulm Med, 9, 5-21. Schirnhofer, L., Lamprecht, B., Vollmer, W. M., Allison, M. J., Studnicka, M., Jensen, R. L., & Buist, A. S. (2007). COPD prevalence in Salzburg, Austria: results from the Burden of Obstructive Lung Disease (BOLD) Study. Chest, 131(1), 29-36. Schneider, C., Jick, S. S., Bothner, U., & Meier, C. R. (2010). COPD and the risk of depression. Chest, 137(2), 341-347. Schnell, K., Weiss, C. O., Lee, T., Krishnan, J. A., Leff, B., Wolff, J. L., & Boyd, C. (2012). The prevalence of clinically-relevant comorbid conditions in patients with physician-diagnosed COPD: a cross-sectional study using data from NHANES 1999-2008. BMC Pulm Med, 12, 26. Seemungal, T. A., Donaldson, G. C., Paul, E. A., Bestall, J. C., Jeffries, D. J., & Wedzicha, J. A. (1998). Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 157(5 Pt 1), 1418-1422. Seneff, M. G., Wagner, D. P., Wagner, R. P., Zimmerman, J. E., & Knaus, W. A. (1995). Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA, 274(23), 1852-1857. Sode, B. F., Dahl, M., & Nordestgaard, B. G. (2011). Myocardial infarction and other co-morbidities in patients with chronic obstructive pulmonary disease: a Danish nationwide study of 7.4 million individuals. Eur Heart J, 32(19), 2365-2375. Soler-Cataluna, J. J., Martinez-Garcia, M. A., Roman Sanchez, P., Salcedo, E., Navarro, M., & Ochando, R. (2005). Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax, 60(11), 925-931. Spencer, S., Calverley, P. M., Burge, P. S., & Jones, P. W. (2004). Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J, 23(5), 698-702. Stage, K. B., Middelboe, T., & Pisinger, C. (2005). Depression and chronic obstructive pulmonary disease (COPD). Impact on survival. Acta Psychiatr Scand, 111(4), 320-323. Suppli Ulrik, C. (2012). Aclidinium Bromide: Clinical Benefit in Patients with Moderate to Severe COPD. Open Respir Med J, 6, 150-154. Sutherland, E. R., & Cherniack, R. M. (2004). Management of chronic obstructive pulmonary disease. N Engl J Med, 350(26), 2689-2697. Tan, W. C., Seale, P., Ip, M., Shim, Y. S., Chiang, C. H., Ng, T. P., Zhong, N. S. (2009). Trends in COPD mortality and hospitalizations in countries and regions of Asia-Pacific. Respirology, 14(1), 90-97. Tashkin, D. P., Celli, B., Senn, S., Burkhart, D., Kesten, S., Menjoge, S., & Decramer, M. (2008). A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med, 359(15), 1543-1554. Taylor, W. D. (2014). Clinical practice. Depression in the elderly. N Engl J Med, 371(13), 1228-1236. van den Berge, M., Vonk, J. M., Gosman, M., Lapperre, T. S., Snoeck-Stroband, J. B., Sterk, P. J., Postma, D. S. (2012). Clinical and inflammatory determinants of bronchial hyperresponsiveness in COPD. Eur Respir J, 40(5), 1098-1105. van Ede, L., Yzermans, C. J., & Brouwer, H. J. (1999). Prevalence of depression in patients with chronic obstructive pulmonary disease: a systematic review. Thorax, 54(8), 688-692. van Manen, J. G., Bindels, P. J., Dekker, F. W., CJ, I. J., van der Zee, J. S., & Schade, E. (2002). Risk of depression in patients with chronic obstructive pulmonary disease and its determinants. Thorax, 57(5), 412-416. Vathenen, A. S., Britton, J. R., Ebden, P., Cookson, J. B., Wharrad, H. J., & Tattersfield, A. E. (1988). High-dose inhaled albuterol in severe chronic airflow limitation. Am Rev Respir Dis, 138(4), 850-855. Vestbo, J., Edwards, L. D., Scanlon, P. D., Yates, J. C., Agusti, A., Bakke, P., Rennard, S. I. (2011). Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med, 365(13), 1184-1192. Vestbo, J., Hurd, S. S., Agusti, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Rodriguez-Roisin, R. (2013). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med, 187(4), 347-365. Vestbo, J., & Lange, P. (2002). Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med, 166(3), 329-332. Viegi, G., Scognamiglio, A., Baldacci, S., Pistelli, F., & Carrozzi, L. (2001). Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration, 68(1), 4-19. Vogelmeier, C., Hederer, B., Glaab, T., Schmidt, H., Rutten-van Molken, M. P., Beeh, K. M., Fabbri, L. M. (2011). Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med, 364(12), 1093-1103. Wagena, E. J., Arrindell, W. A., Wouters, E. F., & van Schayck, C. P. (2005). Are patients with COPD psychologically distressed? Eur Respir J, 26(2), 242-248. Wagena, E. J., van Amelsvoort, L. G., Kant, I., & Wouters, E. F. (2005). Chronic bronchitis, cigarette smoking, and the subsequent onset of depression and anxiety: results from a prospective population-based cohort study. Psychosom Med, 67(4), 656-660. Walters, J. A., Tan, D. J., White, C. J., Gibson, P. G., Wood-Baker, R., & Walters, E. H. (2014). Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 9, CD001288. WHO. (2012). Prevention and control of noncommunicable diseases: guidelines for primary health care in low resource settings, from http://www.who.int/respiratory/copd/burden/en/ World Health Organization. Statistical Dataset. Geneva, S. World Health Organization 2000 3-1-2009, from http://www.who.int/respiratory/copd/burden/en/index.html World_Health_Organization. (2005). Updated Projections of Global Mortality and Burden of Disease, 2002-2030: Data Sources, Methods and Results. Evidence and Information for Policy., from http://www.who.int/healthinfo/statistics/ Xu, W., Collet, J. P., Shapiro, S., Lin, Y., Yang, T., Platt, R. W., Bourbeau, J. (2008). Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations. Am J Respir Crit Care Med, 178(9), 913-920. Yohannes, A. M., Baldwin, R. C., & Connolly, M. J. (2006). Depression and anxiety in elderly patients with chronic obstructive pulmonary disease. Age Ageing, 35(5), 457-459. Zhang, M. W., Ho, R. C., Cheung, M. W., Fu, E., & Mak, A. (2011). Prevalence of depressive symptoms in patients with chronic obstructive pulmonary disease: a systematic review, meta-analysis and meta-regression. Gen Hosp Psychiatry, 33(3), 217-223. Zigmond, A. S., & Snaith, R. P. (1983). The hospital anxiety and depression scale. Acta Psychiatr Scand, 67(6), 361-370. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/53598 | - |
dc.description.abstract | 背景:慢性阻塞性肺病(COPD)是一個病情複雜、病程較長且合併許多共病症(Comorbidities)的慢性病。自2011年起,共病症已列入COPD治療指引以強調其重要性。然而,憂鬱症對於COPD急性發作及死亡之影響,本土資料仍顯不足。
目的:本研究目的為探討憂鬱症共病症在台灣COPD患者的盛行率及其對於COPD急性發作以及死亡之影響。 材料與方法:本研究為固定世代追蹤研究,資料來源為全民健康保險研究資料庫之「2005年百萬承保抽樣歸人檔(LHID2005)」。COPD之診斷必須符合在2005.1.1至2007.12.31當中,至少【兩次門診就診】或【至少一次住院】之出院診斷前三碼有ICD9-CM code: 491,492,496或A323;排除年紀在40歲以下或120歲以上、排除掉同時合併有氣喘之診斷【ICD-9CM code: 493, 至少兩次門診或一次以上住院診斷前三碼】以及排除掉在2008年1月1日以前死亡之個案。憂鬱症(Depression)共病症的診斷包括輕度憂鬱症及重度憂鬱症, ICD9-CM code:輕度憂鬱症(Minor depression):300.4,309.0,309.1,311 以及重度憂鬱症(Major depression):296.2,296.3。共病症之診斷時間為2007.1.1 -2007.12.31期間有門診三次以上或住院一次以上。觀察指標為:有無憂鬱症共病症對於【急性發作(2008.1.1-2008.12.31期間)】以及【死亡(2008.1.1-2011.12.31期間)】之影響。本研究亦使用不同的COPD用藥分組作為校正COPD疾病嚴重度模型,以探討憂鬱症在不同嚴重度的COPD對急性發作以及死亡之影響。整體資料以SAS 9.3版套裝軟體進行資料處理及統計分析。 結果:台灣地區憂鬱症共病症在COPD患者盛行率約為4.1%,遠低於目前大多數文獻研究報導的20-25%,且盛行率並未隨疾病嚴重度增高而上升。憂鬱症的有無並與急性發作之風險(adjusted HR=1.02, 95% CI, 0.77-1.35, p=0.909)以及死亡發生的風險(adjusted HR=1.07, 95% CI, 0.92-1.23, p=0.386)均未達顯著相關,在校正COPD疾病嚴重度後,憂鬱症仍未與急性發作或死亡發生具有顯著相關。 結論:相較於其他COPD常見的共病症,台灣COPD憂鬱症共病症診斷率遠低於其他國家,存在被低估的可能性,因此憂鬱症對於急性發作以及死亡之影響也可能因此而被低估。未來需要進一步結合醫院臨床診療系統進行前瞻性研究,並將憂鬱症評估納入COPD病患常規照護流程。 | zh_TW |
dc.description.abstract | Backgroud: Chronic obstructive pulmonary disease (COPD) is a chronic and complicated disease, which has a longer course and ofen merges many comorbidities. Since 2011, an additional chaper of comorbidities has been included in the COPD treatment guidelines in order to emphasize its importance. However, the impact of depression for COPD acute exacerbations and survival is still insufficient in Taiwan.
Purpose: The purpose of current study is to investigate the prevalence of depressive disorder and its influence on the acute exacerbation and survial in patients with COPD in Taiwan. Materials and Methods: From Taiwan’s National Health Insurance Research Database, the Longitudinal Health Insurance Database (LHID) 2005, we collected data from 4 925 patients, including 985 COPD patients with depressive disorder and 3 940 age- and gender- matched (1:4) control COPD subjects without depressive disorder. Patients newly diagnosed as COPD (with more than 2 times of ambulatory visits diagnosed as COPD【ICD-9-CM: 491, 492, 496 or A323】or 1 times hospitalization with major diagnosis of COPD in 2005-2007 were included in the study. COPD patients aged younger than 40 years old or elder than 120 years old and those who have diagnosed as asthma at the same time were excluded. The comorbidity of depressive disorder included major【ICD-9-CM: 296.2,296.3】and minor depression【ICD-9-CM: 300.4, 309.0, 309.1, 311】were identified during the period of 1 Jan to 31 Dec in 2007. The severity of COPD was adjusted by the different formula of prescriptions. Cox proportional hazards model was performed to evaluate whether depressive disorder was the independent risk factors for acute exacerbation (in 2008) and survival (during 2008-2011) in patients with COPD. Results: The prevalence of depression comorbidity in patients with COPD is about 4.1%, which is far below most of the previous study reported in 20-25%. Meanwhile, the prevalence of depression was not in propotional to the severity of COPD. The findings of our study showed that the risk of acute exacerbation in COPD did not reach significant difference between depression and non-depression group (adjusted HR=1.02, 95% CI, 0.77-1.35, p=0.909). In addition, the results alos showed no significant difference in survival in COPD between depression and non-depression group (adjusted HR=1.07, 95% CI, 0.92-1.23, p=0.386). After adjusting the confounding factor of COPD severity, the influence of depressive disorder on the acute exacerbation and survial in COPD still not reached statistical significance. Conclusion: In comparision to the other common comorbidites in COPD, the prevalence of depressive comorbidity in Taiwan is far lower than other countries. COPD with depressive comorbidity did not increase the risk of acute exacerbation and death even adusting the severity of COPD. Whether this result is contributed to be underestimated of depressive comorbidity in COPD in Taiwan remans uncertain. Further investigation may be needed to corroborate the true prevalence of depressive comorbidity and its influence on COPD through intergrated COPD care process. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T02:26:10Z (GMT). No. of bitstreams: 1 ntu-104-R02848018-1.pdf: 1629994 bytes, checksum: d8b27039f80a1e42a2c49f20793bac34 (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | 致謝.......................................................................................... I
摘要 .........................................................................................II Abstract.................................................................................. III 目錄 .........................................................................................V 表目錄 ...................................................................................VII 圖目錄 ..................................................................................VIII 第一章 緒論 ............................................................................ 1 第一節 研究背景與動機................................................................... 1 第二節 研究目的........................................................... 4 第三節 研究重要性........................................................................... 5 第二章文獻探討 .................................................................... 7 第一節 慢性阻塞性肺病之綜論....................................................... 7 第二節 慢性阻塞性肺病與共病症................................................. 20 第三節 憂鬱症共病症對於慢性阻塞性肺病之影響......................................... 23 第三章 研究設計與方法 .......................................................................... 29 第一節 研究架構............................................................................. 29 第二節 研究假說............................................................................. 30 第三節 研究對象與研究工具......................................................... 31 第四節 資料處理與資料分析......................................................... 32 第四章 研究結果 .................................................................. 39 第一節 研究對象之基本資料描述性統計..................................... 39 第二節 有無憂鬱症共病症對 COPD 病患急性發作及死亡之影響................ 56 第三節 以 Cox proportional hazards model 評估影響COPD 病患急性發作及死 亡之校正後風險比率(adjusted hazard ratio)......................................... 59 第四節 使用用藥模式作為分組,以急性發作及死亡作為模型推估............. 65 第五節 以用藥模式為分組,各組憂鬱症、急性發作以及死亡之描述性統 計..................................................................... 67 第六節 以用藥模式校正疾病嚴重度,探討憂鬱症共病症對 COPD 急性發 作、嚴重急性發作與死亡之影響..................................... 70 第五章 討論 .......................................................................... 80 第一節 研究方法討論..................................................................... 80 第二節 研究結果討論..................................................................... 85 第三節 研究限制討論..................................................................... 93 第六章 結論與建議 .............................................................. 95 第一節 結論................................................................. 95 第二節 建議................................................................. 96 參考文獻 ................................................................................ 98 | |
dc.language.iso | zh-TW | |
dc.title | 憂鬱症在慢性阻塞性肺病(COPD)病患之盛行率及其對COPD病患急性發作及死亡之影響 | zh_TW |
dc.title | The prevalence of depressive disorder and its effect on acute exacerbation and mortality in patients with chronic obstructive pulmonary disease (COPD) | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 林恆慶(Herng-Ching Lin),董鈺琪(Yu-Chi Tung) | |
dc.subject.keyword | 慢性阻塞性肺病,共病症,憂鬱症,急性發作,死亡, | zh_TW |
dc.subject.keyword | COPD,Comorbidity,Depressive disorder,Acute exacerbation,Mortality, | en |
dc.relation.page | 110 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-08-05 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 健康政策與管理研究所 | zh_TW |
顯示於系所單位: | 健康政策與管理研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 1.59 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。